Nordic Nanovector
Kjelsåsveien 168 B
Oslo
0884
Tel: 47-22-18-33-01
Fax: 47-22-58-00-07
Website: http://www.nordicnanovector.no/
Email: mail@nordicnanovector.no
334 articles with Nordic Nanovector
-
Safety Review Committee For Nordic Nanovector's Lymrit 37-01 Trial Recommends Dose Escalation To 20 MBq/kg With Betalutin
11/4/2016
-
Nordic Nanovector: Updated Results From Phase 1/2 Trial Of Betalutin In Non-Hodgkin Lymphoma To Be Presented At American Society of Hematology Annual Meeting In December
11/3/2016
-
Nordic Nanovector: Results From Preclinical Studies Of Betalutin In Combination With Rituximab In Non-Hodgkin Lymphoma Model To Be Presented At American Society of Hematology
11/3/2016
-
Nordic Nanovector And Heidelberg Pharma Enter Collaboration To Develop Novel Antibody-Drug Conjugates (ADCs) Targeting Leukaemias
10/26/2016
-
Nordic Nanovector: Extraordinary General Meeting Held
10/12/2016
-
Nordic Nanovector Announces The Appointment Of Joanna Horobin, MD As Non-Executive Board Director
10/12/2016
-
Nordic Nanovector And LegoChem Biosciences Enter Collaboration To Develop Novel Antibody-Drug Conjugates (ADCS) Targeting Leukemias
10/10/2016
-
Nordic Nanovector – Changes To The Board Of Directors And Notice Of Extraordinary General Meeting
9/21/2016
-
Nordic Nanovector – Notification Of Share Capital Increase
9/13/2016
-
Nordic Nanovector: Lilotomab Pre-Dosing Of NHL Patients Before Betalutin Therapy Lowers Hematological Toxicity With No Reduction In The Tumor Absorbed Radiation Dose
9/6/2016
-
Nordic Nanovector - Financial Calendar
8/31/2016
-
Nordic Nanovector — Results For Second Quarter And Half Year 2016
8/24/2016
-
Nordic Nanovector Completes Recruitment Of The First Cohorts Of Arm 3 And Arm 4 Of Expanded Phase 1/2 Study Of Betalutin In NHL Patients
8/18/2016
-
Nordic Nanovector: Second Quarter And First Half 2016 Results Presentation And Webcast
8/16/2016
-
Nordic Nanovector: Second Quarter And First Half 2016 Results Presentation And Webcast
8/16/2016
-
Nordic Nanovector And Areva Med To Investigate Potential Of Lead-212 Conjugated Anti-Cd37 Antibody For Treating Leukaemias
6/28/2016
-
Nordic Nanovector: Pre-Dosing NHL Patients With HH1 Anti-CD37 Antibody Before Betalutin® Increases Its Pharmacokinetic Exposure And Reduces Its Haematological Toxicity
6/10/2016
-
BIO2016: Nordic Nanovector To Present At BIO International Convention On 7 June 2016
6/3/2016
-
Nordic Nanovector: Allotment Of Restricted Stock Unites (RSUs) To The Board Of Directors
5/31/2016
-
Nordic Nanovector Capital Markets Day 2016 To Highlight Strong Progress Towards Vision Of Becoming A Significant Player In Haematological Cancers
5/31/2016